|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
20.250 -0.550 (-2.644%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 294,726,810 | -2.068% | 300,950,280 | 261,471,723 | 249,120,231 | 203,764,712 |
| Cost of Sales | (272,783,515) | -1.763% | (277,679,599) | (239,814,229) | (228,533,008) | (186,522,837) |
| Gross Profit | 21,943,295 | -5.704% | 23,270,681 | 21,657,494 | 20,587,223 | 17,241,875 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (987,599) | (710,546) | (697,225) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | (388,070) | |
| Other Non-operating Items | (175,995) | -- | 128,201 | 38,093 | 75,259 | 85,763 | |
| Share of Results of Asso. & JCEs | 624,719 | 8.784% | 574,277 | 492,880 | 454,905 | 369,086 | |
| Profit / (Loss) before Taxation | 7,596,489 | -14.319% | 8,866,031 | 8,003,672 | 7,716,947 | 6,217,134 | |
| Taxation | (1,697,273) | -13.966% | (1,972,800) | (1,775,054) | (1,688,416) | (1,413,753) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,195,341) | -21.280% | (2,788,792) | (2,534,874) | (2,445,692) | (1,907,699) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,703,875 | -9.759% | 4,104,439 | 3,693,744 | 3,582,839 | 2,895,682 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,073,865 | -24.260% | 1,417,830 | 1,584,310 | 1,585,248 | 1,427,665 |
| Depreciation & Amortisation | 2,325,197 | 10.734% | 2,099,806 | 2,000,685 | 1,881,920 | 1,591,260 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 119.000 | -9.848% | 132.000 | 118.000 | 115.000 | 93.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 24.207 | -- | 22.304 | 20.265 | 18.518 | 16.653 |
| Remarks: | Real time quote last updated: 14/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,703,875 |
| %Change | -9.759% |
| EPS / (LPS) | RMB 1.190 |
| NBV Per Share (¥) | RMB 24.207 |